EPICENTRX PUBLICATIONS

Data Papers, Reviews, Case Reports, Book Chapters, Presentations and Abstracts.

Recent Publications

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
Reid T, Oronsky A , Caroen S, Carter C, Cabrales P.
Oncotarget. 2018 Apr 5. Data Paper

A review of clinical radioprotection and chemoprotection for oral mucositis
Oronsky B, Burbano E, Kim M, Oronsky N, Lybeck M, Goyal S, Cabrales P, Caroen S, Oronsky A, Carter C.
Translational Oncology. Apr 2018. Review.

A recurrent platinum refractory ovarian cancer patient with a partial response after RRx-001 resensitization to platinum doublet
Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E.
J Investig Med High Impact Case Rep. 2018 Mar 7. Case Report

A note on improved statistical approaches to account for pseudoprogression
Abrouk N, Oronsky B, Caroen S, Ning S, Knox S, Peehl D.
Cancer Chemother Pharmacol. 2018 March, 81(3): 621-626. Data Paper

Sensitization of neuroendocrine prostate cancer by RRx-001
Peehl D, Zhao H, Shoucheng N.
2018 Genitourinary Cancers Symposium; February 8, 2018. Presentation / Abstract

A complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.
Brzezniak C, Oronsky B, Aggarwal R.
Eur Urol. 2018 Feb;73(2):306-307. doi: 10.1016/j.eururo.2017.09.010. Epub 2017 Sep 21. Case Report

Radioprotective effects of RRx-001 on the pathophysiology of the hematopoietic system using a murine radiation model
Kimberly J. Jurgensen, Lynnette H. Cary, Thomas A. Summers, Corey A. Carter, William K. J. Skinner
2017 Radiation Research Society Annual Meeting, Cancun, MX

Nothing but NET: A review of neuroendocrine tumors and carcinomas.
Oronsky B, Ma P, Morgensztern D, Carter C.
Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5. Review.

Electrolyte disorders with platinum-based chemotherapy: Mechanisms, manifestations and management.
Oronsky B, Caroen S, Oronsky A, Dobalian V, Oronsky N, Lybeck M, Reid T, Carter C.
Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20. Review.

What’s new in SCLC? A review.
Oronsky B, Reid T, Oronsky A, Carter C.
Neoplasia. 2017 Oct;19(10):842-847. doi: 10.1016/j.neo.2017.07.007. Epub 2017 Sep 6. Review.

Nitric oxide donor-based cancer therapy: advances and prospects
Huang Z, Fu J, Zhang Y.
J Med Chem. 2017 Sep 28 doi: 10.1021/acs.jmedchem.6b01672. Review.

No patient left behind: The promise of immune priming with epigenetic agents.
Carter C, Oronsky B, Roswarski J, Oronsky A, Oronsky N, Scicinski J, Lybeck H, Kim M, Lybeck M, Reid T.
Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017. Review.

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.
Raghunand N, Scicinski J, Guntle G, Jagadish B, Mash E, Bruckheimer E, Oronsky B, Korn R.
Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24. Data Paper

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.
Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B.
Expert Rev Hematol. 2017 Jun;10(6):575-582. doi: 10.1080/17474086.2017.1324779. Epub 2017 May 22. Data Paper

A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B, Ray C, Spira A, Trepel JB, Carter C, Cottrill H.
Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25. Review.

RRx-001 protects against cisplatin-induced toxicities.
Oronsky B, Reid T, Larson C, Carter C, Brzezniak C, Oronsky A, Cabrales P.
J Cancer Res Clin Oncol. 2017 Apr 17. doi: 10.1007/s00432-017-2416-4. Data Paper

The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry
Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox S, Peehl D.
AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. Presentation / Abstract

Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- β pathway activation and markers for fibrosis
Jha S, Summers T, Zeman K, Brzezniak C, Carter C, Ferry L, Scicinski J, Oronsky B, Caroen S, Trepel J, Cabrales P, Day R.
AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. Presentation / Abstract

Epigenetic and biological effects of 5-azacytidine and RRX-001 on DLD-1 colorectal cancer cell lines
Rory Kokelaar R, Jones H, Beynon J, Harris D, Jenkins G.
AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. Presentation / Abstract

RRx-001 priming of PD-1 inhibition in the treatment of small cell carcinoma of the vagina: A rare gynecological tumor.
Brzezniak C, Oronsky B, Trepel J, Summers T Jr, Cabrales P, Lee M, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck H, Brown J, Reid T, Carter C.
Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr. Case Report

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl D.
Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017. Data Paper

RRx-001: A systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in phase II clinical trials.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox S, Peehl D, Zhao H, Ning S, Cabrales P, Summers T Jr, Reid T, Fitch W, Kim M, Trepel J, Lee M, Kesari S, Abrouk N, Day R, Oronsky A, Ray C, Carter C.
Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Review

A pilot phase 2 study of RRx-001 in advanced lung cancer prior to re-administration of platinum doublets
Brzezniak C, Quinn M, Zeman K, Oronsky B, Scicinski J, Caroen S, Abrouk N, Degesys A, Schmitz B, Peterson P, Roswarski J, Trepel J, Lee M, Lee S, Tomita Y, Day R, Jha S, Carter C.
Journal of Thoracic Oncology January 2017 Volume 12, Issue 1, Supplement, Pages S1090–S1091. Presentation / Abstract

Data Papers

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
Reid T, Oronsky A , Caroen S, Carter C, Cabrales P.
Oncotarget. 2018 Apr 5. Data Paper

A note on improved statistical approaches to account for pseudoprogression
Abrouk N, Oronsky B, Caroen S, Ning S, Knox S, Peehl D.
Cancer Chemother Pharmacol. 2018 March, 81(3): 621-626

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.
Raghunand N, Scicinski J, Guntle G, Jagadish B, Mash E, Bruckheimer E, Oronsky B, Korn R.
Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24.

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.
Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B.
Expert Rev Hematol. 2017 Jun;10(6):575-582. doi: 10.1080/17474086.2017.1324779. Epub 2017 May 22.

RRx-001 protects against cisplatin-induced toxicities.
Oronsky B, Reid T, Larson C, Carter C, Brzezniak C, Oronsky A, Cabrales P.
J Cancer Res Clin Oncol. 2017 Apr 17. doi: 10.1007/s00432-017-2416-4.

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl D.
Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: A superagonist of nitric oxide generation.
Fens M, Cabrales P, Scicinski J, Larkin S, Suh J, Kuypers F, Oronsky N, Lybeck M, Oronsky A, Oronsky B.
Med Oncol. 2016 Aug;33(8):85. doi: 10.1007/s12032-016-0798-9. Epub 2016 Jul 4.

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?
Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B.
Med Oncol. 2016 Jul;33(7):63.

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells
Sharma Das D, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson K.
Leukemia 2016 May 24.

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
Oronsky B, Scicinski J, Cabrales P, Minchinton A.
Clin Epigenetics. 2016 May 11;8:53.

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells
Oronsky B, Scicinski J, Reid T, Oronsky A, Carter C, Oronsky N, Cabrales P.
Discov Med. 2016 Apr;21(116):251-65.

Medical machiavellianism: The tradeoff between benefit and harm with targeted chemotherapy
Oronsky B, Carter C, Scicinska A, Oronsky A, Oronsky N, Lybeck M, Scicinski J.
Oncotarget. 2016 Feb 23;7(8):9041-5.

Epigenetic effects of RRx-001: A possible unifying mechanism of anticancer activity
Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl D.
Oncotarget. 2015 Dec 22;6(41):43172-81.

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001
Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim M, Langecker P, Fanger G.
Redox Biol. 2015 Dec;6:1-8

Safety and activity of RRx-001 in patients with advanced cancer: A first-in-human, open-label, dose-escalation phase 1 study
Reid T, Oronsky B, Scicinski J, Scribner C, Knox S, Ning S, Peehl D, Korn R, Stirn M, Carter C, Oronsky A, Taylor M, Fitch W, Cabrales P, Kim M, Burris H 3rd, Lao C, Abrouk N, Fanger G, Infante J.
Lancet Oncol. 2015 Sep;16(9):1133-42.

Epigenetic approaches to overcoming chemotherapy resistance
Strauss J, Figg W.
Lancet Oncol. 2015 Sep;16(9) 1013-1015

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
Ning S, Sekar T, Scicinski J, Oronsky B, Peehl D, Knox S, Paulmurugan R.
Oncotarget. 2015 Aug 28;6(25):21547-56.

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria
Yalcin O, Oronsky B, Carvalho L, Kuypers FA, Scicinski J, Cabrales P.
Malar J. 2015 May 28;14:218.

Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock
Brouse C, Ortiz D, Su Y, Oronsky B, Scicinski J, Cabrales P.
Asian J Transfus Sci. 2015 Jan-Jun;9(1):55-60.

Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy
Ning S, Bednarski M, Oronsky B, Scicinski J, Knox S.
Biochem Biophys Res Commun. 2014 May 9;447(3):537-42.

Development of methods for the bioanalysis of RRx-001 and metabolites
Scicinski J, Oronsky B, Cooper V, Taylor M, Alexander M, Hadar R, Cosford R, Fleischmann T, Fitch W.
Bioanalysis. 2014 Apr;6(7):947-56.

The implications of hyponitroxia in cancer
Oronsky B, Fanger G, Oronsky N, Knox S, Scicinski J.
Transl Oncol. 2014 Apr;7(2):167-73

Real time dynamic imaging and current targeted therapies in the war on cancer: A new paradigm
Paulmurugan R, Oronsky B, Brouse C, Reid T, Knox S, Scicinski J.
Theranostics. 2013 May 25;3(6):437-47.

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent
Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams C, Fitch W.
Drug Metab Dispos. 2012 Sep;40(9):1810-6.

Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials
Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox S.
Cancer Res. 2012 May 15;72(10):2600-8.

Reviews

A review of clinical radioprotection and chemoprotection for oral mucositis
Oronsky B, Burbano E, Kim M, Oronsky N, Lybeck M, Goyal S, Cabrales P, Caroen S, Oronsky A, Carter C.
Translational Oncology. Apr 2018. Review.

Nothing but NET: A review of neuroendocrine tumors and carcinomas.
Oronsky B, Ma P, Morgensztern D, Carter C.
Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5. Review.

Electrolyte disorders with platinum-based chemotherapy: Mechanisms, manifestations and management.
Oronsky B, Caroen S, Oronsky A, Dobalian V, Oronsky N, Lybeck M, Reid T, Carter C.
Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20. Review.

What’s new in SCLC? A review.
Oronsky B, Reid T, Oronsky A, Carter C.
Neoplasia. 2017 Oct;19(10):842-847. doi: 10.1016/j.neo.2017.07.007. Epub 2017 Sep 6. Review.

Nitric oxide donor-based cancer therapy: advances and prospects
Huang Z, Fu J, Zhang Y.
J Med Chem. 2017 Sep 28 doi: 10.1021/acs.jmedchem.6b01672. Review.

No patient left behind: The promise of immune priming with epigenetic agents.
Carter C, Oronsky B, Roswarski J, Oronsky A, Oronsky N, Scicinski J, Lybeck H, Kim M, Lybeck M, Reid T.
Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017. Review.

A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B, Ray C, Spira A, Trepel JB, Carter C, Cottrill H.
Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25. Review.

RRx-001: A systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in phase II clinical trials.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox S, Peehl D, Zhao H, Ning S, Cabrales P, Summers T Jr, Reid T, Fitch W, Kim M, Trepel J, Lee M, Kesari S, Abrouk N, Day R, Oronsky A, Ray C, Carter C.
Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Review

Turning on the radio: Epigenetic inhibitors as potential radiopriming agents.
Oronsky B, Scicinski J, Kim M, Cabrales P, Salacz M, Carter C, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid T, Oronsky A.
Biomolecules. 2016 Jul 4;6(3). pii: E32. doi: 10.3390/biom6030032. Review.

“No patient left behind”: An alternative to “the war on cancer” metaphor
Oronsky B, Carter C, Oronsky A, Salacz M, Reid T.
Med Oncol. 2016 Jun;33(6):55.

RRx-001, a novel dinitroazetidine radiosensitizer
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.
Invest New Drugs. 2016 Jun;34(3):371-7.

Rockets, radiosensitizers, and RRx-001: An origin story part I
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.
Discov Med. 2016 Mar;21(115):173-80.

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
Carter C, Zeman K, Day R, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B.
Oncotarget. 2016 Mar 19.

Confirmatory trials in the evaluation of anticancer medicinal products in man—PFS2: A measure of therapeutic action-at-a-distance
Oronsky B, Carter C, Reid T, Scicinski J, Oronsky A, Lybeck M, Caroen S, Stirn M, Oronsky N, Langecker P
Neoplasia 2015, 17(9): 716-722

Going viral: A review of replication-selective oncolytic adenoviruses.
Larson C, Oronsky B, Scicinski J, Fanger G, Stirn M, Oronsky A, Reid T.
Oncotarget. 2015 Aug 21;6(24):19976-89. Review.

Episensitization: Defying time’s arrow
Oronsky B, Oronsky A, Lybeck M, Oronsky N, Scicinski J, Carter C, Day R, Rodriguez Orengo J, Rodriguez-Torres M, Fanger G, Reid T.
Front Oncol. 2015 Jun 11;5:134

The war on cancer: A military perspective
Oronsky B, Carter C, Mackie V, Scicinski J, Oronsky A, Oronsky N, Caroen S, Parker C, Lybeck M, Reid T.
Front Oncol. 2014; 4: 387

Rewriting the epigenetic code for tumor resensitization:  A review
Oronsky B, Oronsky N, Scicinski J, Fanger G, Lybeck M, Reid T.
Trans. Onc. 2014, 7, 626-631

Follow the ATP: Tumor energy production. a perspective
Oronsky B, Oronsky N, Fanger G, Parker C, Caroen S, Lybeck M, Scicinski J.
Anticancer Agents Med Chem 2014;14(9):1187-98

Episensitization: Therapeutic tumor resensitization by epigenetic agents: A review and reassessment
Oronsky B, Oronsky N, Knox S, Fanger G, Scicinski J.
Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1187-1198

Development of a safe and efficient two-step synthesis for preparing 1-bromoacetyl-3,3-dinitroazetidine, a novel clinical anticancer candidate
Straessler N, Lesley M, Cannizzo L.
Org. Process Res. Dev. February 15, 2012, pp 512–517 DOI: 10.1021/op2003216

The scarlet letter of alkylation: A mini review of selective alkylating agents
Oronsky B, Reid T, Knox S, Scicinski J.
Trans. Onc. 2012, 21, 226

Beyond antiangiogenesis: Vascular modulation as an anticancer therapy-a review
Oronsky B, Scicinski J, Reid T, Knox S.
Trans. Onc. 2012, 5, 133

Is nitric oxide (NO) the last word in radiosensitization? A review
Oronsky B, Knox S, Scicinski J.
Trans. Onc. 2012, 5, 66

Six degrees of separation: The oxygen effect in the development of radiosensitizers
Oronsky B, Knox S, Scicinski J.
Trans. Onc. 2011, 4, 256

Case Reports

A recurrent platinum refractory ovarian cancer patient with a partial response after RRx-001 resensitization to platinum doublet
Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E.
J Investig Med High Impact Case Rep. 2018 Mar 7.

A complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.
Brzezniak C, Oronsky B, Aggarwal R.
Eur Urol. 2018 Feb;73(2):306-307. doi: 10.1016/j.eururo.2017.09.010. Epub 2017 Sep 21.

RRx-001 priming of PD-1 inhibition in the treatment of small cell carcinoma of the vagina: A rare gynecological tumor.
Brzezniak C, Oronsky B, Trepel J, Summers T Jr, Cabrales P, Lee M, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck H, Brown J, Reid T, Carter C.
Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr.

A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001.
Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid T, Trepel J, Abrouk N, Larson C, Oronsky A, Lybeck H, Day R, Carter C.
Clin Med Insights Oncol. 2016 Nov 6;10:105-108. eCollection 2016.

Conversion of platinum-etoposide-resistant to sensitive SCLC after treatment with the epi-immunotherapeutic RRx-001: A case report.
Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim M, Brown J, Reid T, Larson C, Oronsky A, Day R, Degesys A, Carter C.
Oncol Res Treat. 2016;39(11):720-723. Epub 2016 Sep 19.

Partial response in an RRx-001 primed patient with refractory small-cell lung cancer after a third introduction of platinum doublets.
Carter C, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid T, Brzezniak C.
Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
Carter C, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C.
Respir Med Case Rep. 2016 Apr 24;18:62-5.

Pulmonary tumor thrombotic microangiopathy: A new paraneoplastic syndrome?
Carter C, Scicinski J, Lybeck H, Oronsky B.
Case Rep Oncol. 2016 Apr 23;9(1):246-8.

Whole brain radiotherapy and RRx-001: Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A TITE-CRM phase I/II clinical trial
Kim M, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter C, Oronsky A, Knox S, Caroen S, Oronsky B, Scicinski J, Lawrence T, Lao C.
Transl Oncol. 2016 Apr;9(2):108-13.

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases
Kim M, Parmar H, Cao Y, Knox S, Oronsky B, Scicinski J, Lawrence T, Lao C.
Neuro Oncol. 2016 Mar;18(3):455-6.

RRx-001 in refractory small-cell lung carcinoma: A case report of a partial response after a third reintroduction of platinum doublets.
Carter C, Oronsky B, Caroen S, Scicinski J, Degesys A, Kim M, Oronsky A, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C.
Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.

Immune reactivity and pseudoprogression or tumor flare in a serially biopsied neuroendocrine patient treated with the epigenetic agent RRx-001
Carter C, Schmitz B, Peterson P, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid T, Cabrales P, Brzezniak C.
Case Rep Oncol. 2016 Mar 10;9(1):164-70.

Partial response to platinum doublets in refractory EGFR-positive non-small cell lung cancer patients after RRx-001: Evidence of episensitization
Carter C, Oronsky B, Caroen S, Scicinski J, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C.
Case Rep Oncol. 2016 Jan 28;9(1):62-7.

The case of a zebra that was misdiagnosed as a horse: Pulmonary tumor thrombotic microangiopathy, a new paraneoplastic syndrome, mimicking PD-1-Induced pneumonitis
Carter C, Browning R, Oronsky B, Scicinski J, Brzezniak C.
Case Rep Oncol. 2016 Jan 27;9(1):68-75.

RRx-001-induced tumor necrosis and immune cell Infiltration in an EGFR mutation-positive NSCLC with resistance to EGFR tyrosine kinase inhibitors: A case report
Brzezniak C, Schmitz B, Peterson P, Degesys A, Oronsky B, Scicinski J, Caroen S, Carter C.
Case Rep Oncol. 2016 Jan 15;9(1):45-50.

Flushing out carcinoid syndrome: Beneficial effect of the anticancer epigenetic agent RRx-001 in a patient with a treatment-refractory neuroendocrine tumor
Carter C, Degesys A, Oronsky B, Scicinski J, Caroen S, Oronsky A, Reid T, Cabrales P, Roswarski J.
Case Rep Oncol. 2015 Oct 30;8(3):461-5.

Dysphonia after bevacizumab rechallenge: A case report.
Carter C, Caroen S, Oronsky A, Oronsky B.
Case Rep Oncol. 2015 Oct 14;8(3):423-5. doi: 10.1159/000441122. eCollection 2015 Sep-Dec.

Two case reports of resensitization to previous chemotherapy with the novel hypoxia-activated hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer patients
Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J.
Case Rep Oncol. 2014 Jan 24;7(1):79-85. doi: 10.1159/000358382.

Book Chapters

Episensitization: A new word for a new concept 
Oronsky B, Oronsky A, Lybeck M, Oronsky N, Scicinski J, Carter C, Fanger G, Reid T.
Drug Discovery in Cancer Epigenetics ed. Egger, G, 2016

Discovery and development of RRx-001, a novel nitric oxide and ROS mediated epigenetic modulator
Scicinski J, Oronsky B, Ning S, Fanger G, Knox S, Bednarski M.
Nitric Oxide and Cancer: Pathogenesis and Therapy ed. Bonavida, B, 2015

Hyponitroxia in cancer
Oronsky B, Oronsky N, Lybeck M, Fanger G, Scicinski J.
Nitric Oxide and Cancer: Pathogenesis and Therapy ed. Bonavida, B, 2015

Presentations and Abstracts

Sensitization of neuroendocrine prostate cancer by RRx-001
Peehl D, Zhao H, Shoucheng N.
2018 Genitourinary Cancers Symposium; February 8, 2018

Radioprotective effects of RRx-001 on the pathophysiology of the hematopoietic system using a murine radiation model
Kimberly J. Jurgensen, Lynnette H. Cary, Thomas A. Summers, Corey A. Carter, William K. J. Skinner
2017 Radiation Research Society Annual Meeting, Cancun, MX

Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- β pathway activation and markers for fibrosis
Jha S, Summers T, Zeman K, Brzezniak C, Carter C, Ferry L, Scicinski J, Oronsky B, Caroen S, Trepel J, Cabrales P, Day R.
AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC

Epigenetic and biological effects of 5-azacytidine and RRX-001 on DLD-1 colorectal cancer cell lines
Rory Kokelaar R, Jones H, Beynon J, Harris D, Jenkins G.
AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC

The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry
Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox S, Peehl D.
AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC

A pilot phase 2 study of RRx-001 in advanced lung cancer prior to re-administration of platinum doublets
Brzezniak C, Quinn M, Zeman K, Oronsky B, Scicinski J, Caroen S, Abrouk N, Degesys A, Schmitz B, Peterson P, Roswarski J, Trepel J, Lee M, Lee S, Tomita Y, Day R, Jha S, Carter C.
January 2017 Volume 12, Issue 1, Supplement, Pages S1090–S1091

Improved statistical approaches that account for pseudoprogression in preclinical studies of RRx-001 with immunotherapies
Abrouk E, Scicinski J, Oronsky B, Knox S, Peehl D, Ning S, Fanger G.
AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA

RRx-001 is effective in temozolomide-sensitive and resistant GBM
Steri V, Oronsky B, Scicinski J, Bergers G.
AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA

Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001
Cabrales P, Oronsky B, Scicinski J.
AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA

The hypoxia-selective epigenetic agent, RRx-001, triggers apoptosis and overcomes drug-resistance in multiple myeloma cells
Chauhan D.
ASH 2015, oral presentation, Orlando FL, December 5-8, 2015

RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model
Knox S, Ning S, Peehl D, Oronsky B, Scicinski J.
AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA

‘RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing Phase 2 colorectal cancer study, “ROCKET”’
Reid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Caroen S, Parker P, Scicinski J.
AACR, Chromatin and Epigenetics in Cancer, 2015, Atlanta, GA, September 24 – 27, 2015

‘Restoring efficacy of immunotherapy treatments in oncology with radical oxygen and nitrogen based epigenetic drugs’
Scicinski J.
Invited Presentation at Stem Cells Regenerative Medicine Congress 2015, Washington, D.C., September 2 – 3, 2015

Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer
AACR 2015 Abstract Control Number: 8836
Ann Oncol. 2015 Mar;26(suppl 2):ii4-ii5

A novel immunocompetent murine model for replicating oncolytic adenoviral therapy
Zhang L, Hedjran F, Larson C, Pérez G, Reid T.
2015 Cancer Gene Therapy

RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models
Raghunand N, Scicinski J, Oronsky B, Jagadish B, Mash E, Korn R.
ISMRM 2015

The development of RRx-001, a novel nitric-oxide-mediated epigenetically active anticancer agent
Scicinski J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Reid T.
Invited Presentation at 4th International Workshop on Nitric Oxide in Cancer Therapy, Mar 13 – 14, 2015, Seville, Spain

Early results from a phase 2 study of RRx-001, a novel epigenetic modulator, show resensitization to irinotecan in colorectal cancer
Reid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J.
5th Clinical Epigenetics International Meeting. March 5th – 6th, 2015 – Düsseldorf, Germany

Early results: “ROCKET” a phase II study of RRx-001, a novel triple epigenetic inhibitor, resensitization to irinotecan in colorectal cancer
Carter C, Reid T, Fisher G, Cho-Phan C, Kunz P, Kaiser H, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J.
13th International Congress on Targeted Anticancer Therapies: TAT 2015. Paris, France, mar 2-4, 2015

RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the phase 2 “ROCKET” study
Reid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Scicinski J.
17th Annual Symposium on Anti-Angiogenesis and immune therapies, La Jolla, Feb 19 – 21, 2015

RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study
Reid T, Carney J, Beale K, Chan C, Nguyen H, Stirn M, Ning S, Knox S, Oronsky B, Scicinski J, Caroen S, Parker C, Fanger G, Fisher G.
AACR Translation of the Cancer Genome Conference, San Francisco, California, February 7 – 9, 2015

Anti-myeloma activity of a novel free radical inducer RRx-001
Das D , Tian Z , Ray A , Ravillah D, Song Y, Richardson P, Oronsky B, Scicinski J, Chauhan D, Anderson K.
Blood, 2014, 124 (21) 4712

RRx-001 an EXO-based epigenetic anti-cancer agent in phase 2 clinical trials
Cabrales P, Reid T, Oronsky B, Scicinski J, Chauchan D, Parker C, Caroen S, Fanger G.
ISEV2014 Educational Event: Extracellular Vesicles and Biofluid Biopsies/Companion Diagnostics Conference

 A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent
Reid T, Oronsky B, Infante J, Burris H, Scribner C, Knox S, Stephens J, Fanger G, Scicinski J.
J Clin Oncol 2014 32:5s (suppl; abstr 2578)

RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models
Raghunand N, Scicinski J, Oronsky B, Guntle G, Bruckheimer E, Korn R.
Proceedings: AACR 105th Annual Meeting 2014– Apr 5-9, 2014; San Diego, CA, Abstr 2068

RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase
Cabrales P, Oronsky B, Scicinski J.
Proceedings: AACR 105th Annual Meeting 2014– Apr 5-9, 2014; San Diego, CA, Abstr 1420

Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice
Ning S, Sekar T, Paulmurugan R, Scicinski J, Oronsky B, Peehl D, Knox S.
Proceedings: AACR 105th Annual Meeting 2014– Apr 5-9, 2014; San Diego, CA, Abstr 906

Resensitization to previous chemotherapy with the novel hypomethylating anticancer agent RRx-001
Reid T, Knox S, Ning S, Peehl D, Oronsky B, Stephens J, Fanger G, Korn R, Dad S, Scicinski J.
16th International Symposium on Anti-Angiogenic Therapy, La Jolla, Feb 6 – 8, 2014

‘High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain’
Fitch B, McLaughlin T, Fens M, Scicinski J.
2013 American Chemical Society, Western Regional Meeting, Abstract WRM 267 (Oral presentation)

‘Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent’
Reid T, Infante J, Paul A, Burris H, Oronsky B, Scribner C, Knox S, Stephens J, Santini J, Scicinski J.
Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1 (LB-86)
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC
Also presented at: 15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013

‘RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA)’
Oronsky B, Ning S, Knox S, Cabrales P, Minchinton A, Kuypers F, Fens M, Santini J, Reid T, Scicinski J.
15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013

‘Antivascular activity of RRx-001 in SCCVII and U87 tumors’
Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S.
15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013

‘RRx-001, a hypoxia activated, nitric oxide generating cytotoxic agent: Phase 1 study results’
Scicinski J.
Presentation at 3rd International Workshop on Nitric Oxide in Cancer Therapy, May 31 – Jun3 1, 2013, Kingston Ontario

‘RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors’
Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S.
Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1 (4371)
Proceedings: AACR 103rd Annual Meeting 2012– Mar 31-Apr 4, 2012; Chicago, IL

‘Treatment with a novel dinitroazetidine, ABDNAZ, improves nitrite reductase activity of sickle red blood cells’
Fens M, Larkin S, Scicinski J, Fitch W, Oronsky B, Kuypers F.
Blood (ASH Annual Meeting Abstracts) 2012, 120: Abstract 3246

‘NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells’
Fens M, Larkin S, Morris C, Fitch W, Scicinski J, Oronsky B, Kuypers F.
Blood (ASH Annual Meeting Abstracts) 2011, 118: Abstract 2125

‘Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials’
Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox S.
Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, (676)
Proceedings: AACR 102nd Annual Meeting 2011– Apr 2-6, 2011; Orlando, FL

‘Disposition of 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys, and humans’
Scicinski J, Oronsky B, Fitch W, Taylor M, Luo G, Musick T, Marini J, Adams C, Schicker M, Gohdes M, McKenzie D, Ridgewell R.
ISSX Annual meeting 2011, Abstract P81

Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b
Hedjran F, Shantanu K, Rifat R, Reid T.
Published 2011 in Cancer Gene Therapy

High efficiency transduction of chronic lymphocytic leukemia with adenovirus type 35
Hedjran F, Whitacre D, Kipps T, Reid T.
Published 2006 in Journal of clinical oncology : official journal